Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-8184 Paclitaxel Injectable Emulsion · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| S-8184 Paclitaxel Injectable Emulsion | DRUG | - |
| Experimental Arm: TOCOSOL Paclitaxel | DRUG | Doses of 80, 100 and 120mg/m2 |
Inclusion Criteria: Histologic diagnosis of non small cell lung cancer Relapsed or unresectable stage IIIB or IV disease One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent dosed at 60 mg/m2 or higher per cycle for cisplatin and AUC 6 per cycle for carb...
S-8184 Paclitaxel Injectable Emulsion is an investigational small molecule being studied for the treatment of several cancers, including non-small-cell lung carcinoma, ovarian cancer, urologic neoplasms, and colorectal adenocarcinoma. It has been evaluated in Phase 2 clinical trials for these indications.
S-8184 Paclitaxel Injectable Emulsion is being developed by Achieve Life Sciences, Inc., a company traded on the NASDAQ under the ticker symbol ACHV.
S-8184 Paclitaxel Injectable Emulsion is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All four completed trials were Phase 2 studies.
S-8184 Paclitaxel Injectable Emulsion has been studied in four completed Phase 2 trials: NCT00034151 for ovarian cancer, NCT00034164 for non-small-cell lung cancer, NCT00034177 for urothelial cancer, and NCT00034190 for colorectal adenocarcinoma. These trials enrolled a total of 159 patients.
S-8184 Paclitaxel Injectable Emulsion is a formulation of paclitaxel, a chemotherapy agent. The drug name indicates it is an injectable emulsion of paclitaxel, which is a different delivery form compared to other paclitaxel products.